11thestate Posted - 22 hours ago

$CORT is accepting claims for a $14M settlement it is paying to investors over hiding inflated revenue and sales using illicit sales practices through a related party. Even if the deadline has passed, if you bought between August 2, 2017, and January 31, 2019, you can still file for payment here: https://11thestate.com/cases/corcept-securities-settlement

whiteboytrippin Posted - 3 days ago

$CORT I found this with my often whack but sometimes correct scan scripts seems like it is going to go up.

moorenard1 Posted - 4 days ago

@gucag006 The drop in $CORT pretty much mirrors the $XBI over the last week. I think this is an overreaction to RFK Jr , but I actually think his policies could end up benefiting smaller biotechs like Corcept in the longer run. My only saving grace this week is that my big positions in $ET and $EPD have gone up quite nicely. I am not as smartly diversified as you @gucag006 , but definitely took the sting off my overly large corcept position this week.

Tano4 Posted - 5 days ago

$CORT need some of those Q4 results to come in and put some wind back in our sails

gucag006 Posted - 5 days ago

$LXRX $CORT bloody cat today no matter how you skin it. The thing making my day a little more tolerable is diversification. While the market tanks, two of my major positions YCL (2x against yen) and SQQQ (3x against NASDAQ-100) are doing extremely well - up 3.4% and 7.4%, respectively. This types of diversification is absolutely necessary heading into the tumultuous market currently sitting near the top as seen in the 10Y S&P500 chart below.

gucag006 Posted - 5 days ago

$CORT Not a market technician, but the "gap" on 11/6 is filled anyway - making room for next wave up. If you haven't closed your short position today, shorties, you may not have another chance like today's SP again, GLTA!

Cutlass Posted - 6 days ago

$CORT Missed that Halloween ER dip ☹👀🎃

bubbarayjr Posted - 1 week ago

$CORT Recorlev is the L Isomer of Ketoconazole an old anti-fungal medication. Many years ago, severe adverse reactions were reported to the FDA soon after the FDA began the FAERS (Fed Adverse Events Reporting System). Ketoconazole was one of the first meds to receive the ominous BLACK-BOX WARNING designation. MDs always avoid using products with the BB warning when there are better alternatives because not doing so puts their patients at unnecessary risk and opens them up to liability issues.

bubbarayjr Posted - 1 week ago

$CORT Competition from Recorlev?? Here's why MD's will not use it. From the Package Insert: Indication & Important Safety Information for Recorlev® (levoketoconazole) BOXED WARNING: HEPATOTOXICITY AND QT PROLONGATION HEPATOTOXICITY Cases of hepatotoxicity with fatal outcome or requiring liver transplantation have been reported with oral ketoconazole. Some patients had no obvious risk factors for liver disease. Recorlev is associated with serious hepatotoxicity. Evaluate liver enzymes prior to and during treatment. QT PROLONGATION Recorlev is associated with dose-related QT interval prolongation. QT interval prolongation may result in life-threatening ventricular dysrhythmias such as torsades de pointes. Perform ECG and correct hypokalemia and hypomagnesemia prior to and during treatment.

Bullseye1285 Posted - 1 week ago

$XERS I’m assuming some of the selling was due to this from $CORT Future Competition?

gucag006 Posted - 1 week ago

$CORT As of 10/31/24, the SI as reported by NASDAQ stands at 18.8M shares, decreased by 1.9M from SI as of 10/15/24. As seen from the SP chart below that this drop in SI was before the major runup in SP during the past two weeks. We will get another update from NASDAQ on 11/26/24 for SI up to 11/14/24, and I expect a major drop in SI as the shorties close their positions and hand in the towels.

bubbarayjr Posted - 1 week ago

$CORT agree. The $3B guidance is based on a market size that is now 60 times larger and Relacorilant coming on board with a much better side effect profile and ease of dispensing. ALS, CA and NASH are icing on the cake. I think big pharma will come knocking in the near future but after the super hot price action yesterday it may be already underway imo

moorenard1 Posted - 1 week ago

$CORT For those who are new to CORT or think the recent run up might cool off. It won’t. The stock is on its way to over $100. Consider two facts: (1) Since the launch of Korlym in 2012, management has always met or exceeded guidance. 12 years of management doing exactly what they say they will. (2) Management has publicly stated that they will get to $3 billion in annual sales. $3 billion in sales will yield something like $20-$25 in earnings per share. Using standard multiples, the shares will be worth $150 or better. This assumes cancer, ALS, and everything else fails. If cancer or ALS work, the stock will get to $350 quickly. $60 is a bargain. At $60 CORT is the most undervalued company in the space. I am buying more and encourage everyone to do the same.

bubbarayjr Posted - 1 week ago

$CORT With the huge move over the last couple of months and especially yesterday I would expect that to happen after big news or at least a believable rumor. Instead it’s crickets. Yes, CORT had impressive earnings which may very well be driving this move but it seems much more than that to me. After many years of investing and watching moves like this, most occurred after big news or rumors likely to be true. And most of the time when a move like this occurred without any of the above it was due to big news behind the scene. We learn soon enough what’s causing this move and it appears to be very positive imo.

bubbarayjr Posted - 1 week ago

$CORT Rumors? With the huge move over the last couple of months and especially yesterday I would expect that to happen after big news or at least a believable rumor. Instead it’s crickets. Yes, CORT had impressive earnings which may very well be driving this move but it seems much more than that to me. After many years of investing and watching moves like this, most occurred after big news or rumors likely to be true. And most of the time when a move like this occurred without any of the above it was due to big news behind the scene. We learn soon enough what’s causing this move and it appears to be very positive imo.

ST_ck Posted - 1 week ago

$CORT big drop next week

ST_ck Posted - 1 week ago

$CORT looking at the earnings, this stock is overvalued. Gains are happening because of the sector rotation and overall health care gains. It’s a good stock but way overvalued.

gucag006 Posted - 1 week ago

$CORT Squeeze and squeeze hard. As of 10/16/24, 105M shares outstanding, 20.7M shares shorted. For those watching technical charts and thinking pull-backs, I caution you that multiple catalysts coming such as Relacorilant NDA and subsequent FDA approve, and ROSELLA (ovarian cancer) p3 trial readout, NDA & approval, which will reset your technical charts instantaneously, then you have to rebuild your technical charts from scratch.

bubbarayjr Posted - 1 week ago

$CORT major squeeze under way

ST_ck Posted - 1 week ago

$CORT over valued.

100Financial Posted - 1 week ago

$CORT Technical analysis indicates a pull back coming. Started a short position for swing.

Tano4 Posted - 1 week ago

$CORT one of the best trade of the year so far Been accumulating so many shares along the way

Stocker4949 Posted - 1 week ago

$CORT I hereby affirm the new target price of CORT to $80.

stealthCash87 Posted - 1 week ago

MYNZ 🔥 Perfect time to jump in, cheapest dip!!! Shorts volume increased. HUGE PR drop incoming before the Nov 13 meeting, so compliance is coming, no RS needed. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7.CEO teased big plans ahead. 8.Offering Deal $CORT $CRNX

bubbarayjr Posted - 1 week ago

$CORT buyout or positive news from open label ROSELLA study imo

bubbarayjr Posted - 1 week ago

$CORT Many decades ago (I'm an old guy) my pharmacology professor, the best college professor I was blessed to train under, began our study into steroids by saying corticosteroids are a remarkable class of drugs that do amazing things however the side effects from long-term use severely limit their potential. He went on to say if/when a pharmaceutical company figures out how to keep the good and eliminate the bad they truly will have created a magic pill. It was many years later (well more than 10) that I stumbled upon CORT and the science behind the company. I think CORT may just have found that magic pill(s) and wish my old professor was still alive to see it today.

dave2ta Posted - 1 week ago

@SparkyReturns BTW, did you see the recent jumps by $CORT??? It's one of my favorite holdings, along with $XERS of course... 👍

EingeLTrade Posted - 2 weeks ago

$65 next for $CORT

UncleStock Posted - 2 weeks ago

$EXEL $UTHR $CORT $NBIX suggested for $BTK US ARCA Biotechnology - value screen: https://zpr.io/tWJwE

swingingtech Posted - 2 weeks ago

$CORT $IONS $COLL https://wallstreetwaves.com/corcept-therapeutics-stock-surges-61-in-2024-a-must-buy/